Yale School of Medicine

Princeton University

President & CEO

Mustang Bio, Inc. (Nasdaq: MBIO), is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X¬SCID.  These institutions include St. Jude Children's Research Hospital, City of Hope, Fred Hutchinson Cancer Research Center, and Nationwide Children's Hospital.

Mustang Bio

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC(R) protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Arvinas Inc.

President and CEO

Executive Global Program Head for the Novartis-University of Pennsylvania CAR T (chimeric antigen receptor modified T cells) collaboration.  CTL019 (tisagenlecleucel) targets CD19-positive malignancies and is the lead program for this collaboration.  In 2017 it became the first FDA-approved CAR T therapy and is now marketed in the US as Kymriah.

Manuel Litchman